Trial Profile
Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Liver metastases; Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SURTIME
- 27 Oct 2021 Results of post-hoc analysis published in the BJU International.
- 26 Jul 2020 Status changed from active, no longer recruiting to completed.
- 26 Jul 2020 Results of post-hoc analysis presented at the 35th Congress of the European Association of Urology